Senior Dog Pre-Anesthetic Workup Protocol

This is a very common and important clinical question. Anesthetic safety in a senior patient with newly identified heart disease hinges on properly staging that disease. A Grade II/VI murmur in a 14-year-old small breed dog is most likely degenerative mitral valve disease (DMVD), but we need to know if it's hemodynamically significant.

Here is my assessment and plan:

1. Pre-Anesthetic Diagnostics (The "Must-Haves"):
Your planned lab work (CBC, chemistry, T4, UA) is excellent. From a cardiac standpoint, I would consider the following essential:

* Thoracic Radiographs (3-view): This is non-negotiable. We need a baseline Vertebral Heart Score (VHS) and, most critically, to evaluate the pulmonary vasculature and parenchyma. The goal is to rule out subclinical or early congestive heart failure (CHF), which would dramatically increase anesthetic risk.
* Pre-anesthetic Echocardiogram: This is the gold standard for staging and risk assessment. It will differentiate ACVIM Stage B1 (structural disease, no remodeling) from Stage B2 (remodeling, i.e., left atrial enlargement). This distinction is key: a Stage B2 patient has a more compromised cardiovascular system and may already be on pimobendan, which has anesthetic implications. The echo also assesses systolic function and screens for pulmonary hypertension, both of which directly guide our drug choices.
* Sleeping Respiratory Rate (SRR): Before any of this, have the owner count the SRR at home for 2-3 nights. A consistent rate <30 breaths/min is very reassuring against occult CHF.

2. ASA Classification:
This is entirely dependent on the diagnostic findings:
* ASA II: If echo shows Stage B1 disease and rads are clear.
* ASA III: If echo shows Stage B2 disease (significant LA enlargement, normal function) and rads are clear.
* ASA IV: If there is any evidence of CHF, severe systolic dysfunction, or significant pulmonary hypertension. The procedure should be postponed in this case until the patient is stabilized.

3. Anesthetic & Fluid Protocol Recommendations (Coordination with Pharmacology):
The goal is to maintain forward flow and avoid excessive changes in heart rate, contractility, and vascular resistance.

* Anesthetic Drugs: Avoid drugs that cause significant vasodilation (like acepromazine, especially at higher doses) or profound myocardial depression. A neuroleptanalgesic approach with an opioid and benzodiazepine is often ideal. I'll defer to Dr. Voss for specific drug protocols.
* Fluid Therapy: This is critical. These patients are highly susceptible to volume overload. I recommend a conservative IV fluid rate of 2-3 mL/kg/hr. Avoid any large fluid boluses.
* Monitoring: Standard monitoring is essential, but I would strongly advocate for invasive arterial blood pressure monitoring if available. It provides the most accurate, real-time data to guide interventions. Pay close attention to trends in blood pressure and heart rate.

I will ask my colleagues to provide more detail on their specific areas.

Dr. Lin (Radiology): Please comment on the key radiographic findings you'd be looking for to assess cardiac status and risk in this patient.
Dr. Voss (Clinical Pharmacology): Based on a presumptive diagnosis of DMVD Stage B1 or B2, please provide a sample cardio-stable anesthetic protocol (pre-med, induction, maintenance).

Colleague,

For this patient, pre-anesthetic thoracic radiographs are not optional; they are strongly indicated. A 14-year-old small breed dog with a new or uncharacterized Grade II/VI murmur has a high index of suspicion for myxomatous mitral valve disease (MMVD). Our primary goals with imaging are to stage the cardiac disease and screen for occult pathology that would alter anesthetic risk.

A three-view thoracic series (right lateral, left lateral, and either a ventrodorsal or dorsoventral view) is the minimum standard. This allows us to perform a complete assessment and reduces the chance of missing small pulmonary nodules.

My systematic evaluation would focus on these key areas:

Cardiac Size and Shape: I will measure the Vertebral Heart Score (VHS) to objectively quantify heart size. More importantly, I will look for specific evidence of left atrial enlargement—dorsal deviation of the distal trachea on the lateral view and splaying of the mainstem bronchi on the DV/VD view. This is the most critical radiographic indicator for staging MMVD.

Pulmonary Vasculature and Parenchyma: I will carefully assess the pulmonary veins. Any enlargement relative to the corresponding pulmonary arteries is a sign of elevated left atrial pressure and impending congestive heart failure (CHF). I will also scrutinize the perihilar and caudodorsal lung fields for any increase in unstructured interstitial opacity, which could represent early cardiogenic edema. Anesthetizing a patient with subclinical CHF significantly increases morbidity and mortality.

Geriatric Screen: Beyond the heart and lungs, the study serves as a general screen. I will evaluate for evidence of metastatic disease, tracheal collapse (common in this signalment), or other intrathoracic abnormalities.

The radiographic findings will directly inform the next steps. If cardiomegaly, specifically left atrial enlargement, is present, I will strongly recommend that Dr. Obi perform a pre-anesthetic echocardiogram for definitive staging and functional assessment. My report will provide the objective data needed to guide that decision and to help Dr. Voss tailor the anesthetic protocol appropriately.

Colleagues,

This is a classic and important case where pharmacology intersects directly with patient safety. A 14-year-old patient has minimal physiologic reserve, so our drug choices and dosing need to be precise. The Grade II/VI murmur is a significant variable; I'll focus on the pharmacological implications, but Dr. Obi's input after an echo will be critical for tailoring the final plan.

From a pharmacologic standpoint, here is my approach to protocol design for this patient:

Pre-medication: The goal is synergistic sedation and pre-emptive analgesia with minimal cardiovascular depression.

* Recommend: A neuroleptanalgesic combination. A full mu-opioid agonist (methadone or hydromorphone at a reduced geriatric dose, e.g., 0.1-0.2 mg/kg IM) combined with a benzodiazepine (midazolam 0.2 mg/kg IM). This provides excellent sedation and analgesia with minimal impact on cardiac contractility or blood pressure. The opioid-induced bradycardia is usually mild and responsive to anticholinergics if it becomes hemodynamically significant.
* Avoid: Acepromazine. Its long-acting, non-reversible alpha-1 antagonism causes vasodilation that this patient's heart may not be able to compensate for, leading to refractory hypotension. Dexmedetomidine should also be used with extreme caution or avoided; the intense initial vasoconstriction and reflex bradycardia can be poorly tolerated in patients with underlying cardiac disease.

Induction:

* Slow titration to effect is more important than the specific agent. Both propofol and alfaxalone cause dose-dependent vasodilation and hypotension. I recommend calculating the full dose, then administering it in 25% increments IV, waiting 30-60 seconds between boluses until intubation is possible. This minimizes the peak plasma concentration and subsequent hemodynamic slump. Co-induction with a small dose of ketamine (0.5-1 mg/kg IV) can reduce the required dose of propofol/alfaxalone, but should only be done after Dr. Obi has ruled out hypertrophic cardiomyopathy.

Analgesia (Multimodal Approach):

* Local Blocks are Essential: This is the most important part of the plan. Effective maxillary and mandibular nerve blocks will dramatically reduce the amount of inhalant required to maintain an appropriate anesthetic plane. Lowering the MAC of isoflurane or sevoflurane is the single best thing we can do to maintain blood pressure and organ perfusion.
* NSAID Administration: This is a high-risk decision point. Intra-operative hypotension is common and can precipitate acute kidney injury, especially in a 14-year-old. I would not give an NSAID pre-operatively. If, and only if, the procedure is smooth, the patient remains normotensive (MAP > 65 mmHg) throughout, and post-operative blood work shows stable renal values, then a single dose of a short-acting NSAID (e.g., robenacoxib) could be considered for post-operative anti-inflammatory effects. Opioids remain the safer first-line choice for immediate post-op pain.

Recovery:

* Remember that hypothermia slows hepatic metabolism. A cold patient will have a prolonged recovery from both injectable and inhalant agents. Aggressive thermal support is not just for comfort; it's a critical aspect of predictable pharmacokinetics.

I'll defer to Dr. Obi for the definitive cardiac assessment and fluid therapy plan—we need to avoid volume overload. Dr. Lin's interpretation of chest radiographs will be key for identifying pulmonary edema or significant cardiomegaly that would further modify our approach.